ClinicalTrials.gg
CompletedNCT04971785WAYFINDUpdated Nov 26, 2025Results posted

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

A Phase 2 interventional study of Semaglutide (SEMA) and Cilofexor (CILO)/Firsocostat (FIR) in Nonalcoholic Steatohepatitis, sponsored by Gilead Sciences. Completed at 242 sites in 7 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
457
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing semaglutide in Non-alcoholic Fatty Liver Disease — 4 open to participants now, 8 under way, 1 of them phase 3. Semaglutide · Non-alcoholic Fatty Liver Disease.

Enrollment
2nd of 16
457 · median 88
Started
2021
with 3 others
Phase 2
8 of 16
2 open now
Registered
9th of 16
by date
Lead sponsor
1 of 16
Gilead Sciences

Among the 16 studies testing semaglutide in Non-alcoholic Fatty Liver Disease, this one is the 2nd largest by enrollment, is one of 4 that started in 2021, is one of 8 in phase 2, and was the 9th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

4 of the 16 studies testing semaglutide in Non-alcoholic Fatty Liver Disease are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing semaglutide in Non-alcoholic Fatty Liver Disease, or all of them as a file.
02

Study summary

The goal of this clinical study is to understand whether the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firsocostat (CILO/FIR), cause fibrosis improvement and Nonalcoholic Steatohepatitis (NASH) resolution in participants with cirrhosis due to NASH.

03

Conditions studied

  • Nonalcoholic Steatohepatitis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Liver consistent with cirrhosis (F4) due to nonalcoholic steatohepatitis (NASH) in the opinion of the central reader. In individuals who have never had a liver biopsy, a screening liver biopsy may be performed.
  • Screening laboratory parameters as determined by the study central laboratory:

    • Estimated (eGFR) ≥ 30 mL/min/1.73 m\^2, as calculated by the Modification of Diet in Renal Disease (MDRD) equation.
    • (HbA1c) ≤ 10%
    • (INR) ≤ 1.4, unless due to therapeutic anticoagulation
    • count ≥ 125,000/µL
    • (ALT) \< 5 x (ULN)
    • Serum albumin ≥ 3.5 g/dL
    • Serum alkaline phosphatase (ALP) ≤ 2 x ULN
  • (BMI) ≥ 23 kg/m\^2 at screening.

Key Exclusion Criteria:

  • Prior history of decompensated liver disease, including ascites, hepatic encephalopathy (HE), or variceal bleeding.
  • (CP) score > 6 at screening, unless due to an alternative etiology such as Gilbert's syndrome or therapeutic anticoagulation.
  • Model for End-stage Liver Disease (MELD) score > 12 at screening, unless due to an alternative etiology such as therapeutic anticoagulation.
  • Other causes of liver disease based on medical history and/or central reader review of liver histology, including but not limited to: alcoholic liver disease, disorders (eg, primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis), drug-induced hepatotoxicity, Wilson disease, iron overload, or alpha-1-antitrypsin deficiency.
  • Chronic virus (HBV) infection (HBsAg positive), or Chronic virus (HCV) infection (HCV antibody and HCV ribonucleic acid (RNA) positive). Individuals cured of HCV infection less than 2 years prior to the screening visit are not eligible.
  • History of liver transplantation.
  • Current or prior history of hepatocellular carcinoma (HCC).
  • Men who habitually drink greater than 21 units/week of alcohol or women who habitually drink greater than 14 units/week of alcohol (1 unit is equivalent to 12 ounce (oz)/360 mL of beer, a 4 oz/120 mL glass of wine, or 1 oz/30 mL of hard liquor).

    • For individuals on vitamin E regimen ≥ 800 IU/day, or pioglitazone, dose must be stable, in the opinion of the investigator for at least 180 days prior to the historical or screening liver biopsy.
    • For individuals on medications for diabetes, dose must be stable, in the opinion of the investigator, for at least 90 days prior to the historical or screening liver biopsy.
  • History of type 1 diabetes.
  • Treatment with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) in the period from 90 days prior to the screening visit and for individuals with a qualifying historical liver biopsy, for 90 days prior to the date of the historical liver biopsy.
  • For individuals who have not completed a series of an authorized coronavirus disease 2019 (COVID-19) vaccination regimen prior to screening, a positive result for COVID-19 on severe acute respiratory syndrome (SARS)-coronavirus 2 (CoV-2) reverse transcriptase-polymerase chain reaction (RT-PCR) test.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
457 participants (actual)

Study arms

  • Experimental
    SEMA + CILO/FIR FDC

    Participants will receive semaglutide (SEMA) 3.0 mg/mL, once weekly and cilofexor and firsocostat (CILO/FIR) 30 mg/20 mg fixed-dose combination (FDC) tablet, once daily up to 72 weeks.

    Drug: Semaglutide (SEMA) · Drug: Cilofexor (CILO)/Firsocostat (FIR)

  • Experimental
    SEMA + PTM CILO/FIR

    Participants will receive SEMA 3.0 mg/mL, once weekly and Placebo-To-Match (PTM) CILO/FIR FDC tablet, once daily up to 72 weeks.

    Drug: Semaglutide (SEMA) · Drug: PTM CILO/FIR

  • Experimental
    PTM SEMA + CILO/FIR FDC

    Participants will receive PTM SEMA, once weekly and CILO/FIR 30 mg/20 mg FDC tablet, once daily up to 72 weeks.

    Drug: Cilofexor (CILO)/Firsocostat (FIR) · Drug: PTM SEMA

  • Placebo comparator
    PTM SEMA + PTM CILO/FIR

    Participants will receive PTM SEMA, once weekly and PTM CILO/FIR FDC tablet, once daily up to 72 weeks.

    Drug: PTM SEMA · Drug: PTM CILO/FIR

Interventions

  • Administered as subcutaneous (SC) injection

  • DrugCilofexor (CILO)/Firsocostat (FIR)

    Drug pages: Cilofexor · Firsocostat

    Tablets administered orally

    Also known as: GS-9674/GS-0976

  • DrugPTM SEMA

    Administered as SC injection

  • DrugPTM CILO/FIR

    Tablets administered orally

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 72 in Semaglutide (SEMA) + Cilofexor/Firsocostat (CILO/FIR) Fixed Dose Combination (FDC) Versus Placebo Groups

    Fibrosis improvement was defined as ≥ 1-stage decrease from baseline in fibrosis according to the NASH clinical research network (CRN) classification. Worsening of NASH was defined as ≥ 1-point increase from baseline in hepatocellular ballooning or lobular inflammation. Clopper-Pearson method was used in outcome measure analysis in each arm. Percentages were rounded-off.

    Time frame: Week 72

Secondary outcomes

  1. Percentage of Participants Who Achieved ≥1-Stage Improvement in Fibrosis Without Worsening of NASH at Week 72 in SEMA + CILO/FIR FDC Versus SEMA Alone

    Fibrosis improvement was defined as ≥ 1-stage decrease from baseline in fibrosis according to the NASH CRN classification. Worsening of NASH was defined as ≥ 1-point increase from baseline in hepatocellular ballooning or lobular inflammation. Clopper-Pearson method was used in outcome measure analysis in each arm. Percentages were rounded-off.

    Time frame: Week 72

  2. Percentage of Participants With NASH Resolution Without Worsening in Fibrosis at Week 72 in SEMA + CILO/FIR FDC Versus Placebo Groups

    NASH resolution is defined as lobular inflammation of 0 or 1 and hepatocellular ballooning of 0. Worsening in fibrosis was defined as a change in fibrosis worsening stage as per NASH CRN criteria. Clopper-Pearson method was used in outcome measure analysis in each arm. Percentages were rounded-off.

    Time frame: Week 72

  3. Percentage of Participants With NASH Resolution Without Worsening in Fibrosis In Participants Treated With SEMA + CILO/FIR FDC Versus CILO/FIR Alone Groups

    NASH resolution is defined as lobular inflammation of 0 or 1 and hepatocellular ballooning of 0. Worsening in fibrosis was defined as a change in fibrosis worsening stage as per NASH CRN criteria. Clopper-Pearson method was used in outcome measure analysis in each arm. Percentages were rounded-off.

    Time frame: Week 72

07

Results

Posted Nov 26, 2025

Participant flow

Participants were enrolled at study sites in the United States, Canada, France, Japan, Australia and Spain.

Participant flow — Overall Study
MilestoneSEMA + CILO/FIR FDCSEMA + PTM CILO/FIRPTM SEMA + CILO/FIR FDCPTM SEMA + PTM CILO/FIR
Started12512412385
Completed1031049165
Not completed22203220
Withdrew: Withdrew consent55177
Withdrew: Adverse event7863
Withdrew: Lost to follow-up2167
Withdrew: Protocol violation3112
Withdrew: Investigator's discretion3110
Withdrew: Randomized but never treated1201
Withdrew: Death0110
Withdrew: Site terminated by sponsor1100

Outcome measures

PrimaryPercentage of Participants Who Achieved ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 72 in Semaglutide (SEMA) + Cilofexor/Firsocostat (CILO/FIR) Fixed Dose Combination (FDC) Versus Placebo Groups

Fibrosis improvement was defined as ≥ 1-stage decrease from baseline in fibrosis according to the NASH clinical research network (CRN) classification. Worsening of NASH was defined as ≥ 1-point increase from baseline in hepatocellular ballooning or lobular inflammation. Clopper-Pearson method was used in outcome measure analysis in each arm. Percentages were rounded-off.

Time frame:
Week 72
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 72 in Semaglutide (SEMA) + Cilofexor/Firsocostat (CILO/FIR) Fixed Dose Combination (FDC) Versus Placebo Groups
percentage of participantsSEMA + CILO/FIR FDCPTM SEMA + PTM CILO/FIR
Percentage of Participants Who Achieved ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 72 in Semaglutide (SEMA) + Cilofexor/Firsocostat (CILO/FIR) Fixed Dose Combination (FDC) Versus Placebo Groups13.7 (8.2 to 21.0)8.3 (3.4 to 16.4)
Statistical analysis
  • SEMA + CILO/FIR FDC vs PTM SEMA + PTM CILO/FIR · Stratified Mantel-Haenszel test · p = 0.2289 · Difference in percentages: 5.7 · 95% CI -3.6 to 14.9Percentage difference and 95% confidence interval (CI) between each pair of treatment groups were from stratified Mantel-Haenszel test with baseline diabetes status and baseline enhanced liver fibrosis (ELF) category as stratification factors.
SecondaryPercentage of Participants Who Achieved ≥1-Stage Improvement in Fibrosis Without Worsening of NASH at Week 72 in SEMA + CILO/FIR FDC Versus SEMA Alone

Fibrosis improvement was defined as ≥ 1-stage decrease from baseline in fibrosis according to the NASH CRN classification. Worsening of NASH was defined as ≥ 1-point increase from baseline in hepatocellular ballooning or lobular inflammation. Clopper-Pearson method was used in outcome measure analysis in each arm. Percentages were rounded-off.

Time frame:
Week 72
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ≥1-Stage Improvement in Fibrosis Without Worsening of NASH at Week 72 in SEMA + CILO/FIR FDC Versus SEMA Alone
percentage of participantsSEMA + CILO/FIR FDCSEMA + PTM CILO/FIR
Percentage of Participants Who Achieved ≥1-Stage Improvement in Fibrosis Without Worsening of NASH at Week 72 in SEMA + CILO/FIR FDC Versus SEMA Alone13.7 (8.2 to 21.0)15.6 (9.6 to 23.2)
Statistical analysis
  • SEMA + CILO/FIR FDC vs SEMA + PTM CILO/FIR · Stratified Mantel-Haenszel test · p = 0.6959 · Difference in percentages: -1.8 · 95% CI -11.1 to 7.4Percentage difference and 95% CI between each pair of treatment groups presented were from stratified Mantel-Haenszel test with baseline diabetes status and baseline ELF category as stratification factors.
SecondaryPercentage of Participants With NASH Resolution Without Worsening in Fibrosis at Week 72 in SEMA + CILO/FIR FDC Versus Placebo Groups

NASH resolution is defined as lobular inflammation of 0 or 1 and hepatocellular ballooning of 0. Worsening in fibrosis was defined as a change in fibrosis worsening stage as per NASH CRN criteria. Clopper-Pearson method was used in outcome measure analysis in each arm. Percentages were rounded-off.

Time frame:
Week 72
Reported as:
Number · percentage of participants
Percentage of Participants With NASH Resolution Without Worsening in Fibrosis at Week 72 in SEMA + CILO/FIR FDC Versus Placebo Groups
percentage of participantsSEMA + CILO/FIR FDCPTM SEMA + PTM CILO/FIR
Percentage of Participants With NASH Resolution Without Worsening in Fibrosis at Week 72 in SEMA + CILO/FIR FDC Versus Placebo Groups57.3 (45.9 to 68.2)22.4 (11.8 to 36.6)
Statistical analysis
  • SEMA + CILO/FIR FDC vs PTM SEMA + PTM CILO/FIR · Stratified Mantel-Haenszel test · p = <0.0001 · Difference in percentages: 35.7 · 95% CI 18.8 to 52.6Percentage difference and 95% CI between each pair of treatment groups presented are from stratified Mantel-Haenszel test with baseline diabetes status and baseline ELF category as stratification factors.
SecondaryPercentage of Participants With NASH Resolution Without Worsening in Fibrosis In Participants Treated With SEMA + CILO/FIR FDC Versus CILO/FIR Alone Groups

NASH resolution is defined as lobular inflammation of 0 or 1 and hepatocellular ballooning of 0. Worsening in fibrosis was defined as a change in fibrosis worsening stage as per NASH CRN criteria. Clopper-Pearson method was used in outcome measure analysis in each arm. Percentages were rounded-off.

Time frame:
Week 72
Reported as:
Number · percentage of participants
Percentage of Participants With NASH Resolution Without Worsening in Fibrosis In Participants Treated With SEMA + CILO/FIR FDC Versus CILO/FIR Alone Groups
percentage of participantsSEMA + CILO/FIR FDCPTM SEMA + CILO/FIR FDC
Percentage of Participants With NASH Resolution Without Worsening in Fibrosis In Participants Treated With SEMA + CILO/FIR FDC Versus CILO/FIR Alone Groups57.3 (45.9 to 68.2)31.8 (22.3 to 42.6)
Statistical analysis
  • SEMA + CILO/FIR FDC vs PTM SEMA + CILO/FIR FDC · Stratified Mantel-Haenszel test · p = 0.0006 · Difference in percentages: 26.1 · 95% CI 11.3 to 40.9Percentage difference and 95% CI between each pair of treatment groups presented were from stratified Mantel-Haenszel test with baseline diabetes status and baseline ELF category as stratification factors.

Adverse events

Collected over All-cause mortality and Adverse events: Up to 72 weeks plus 35 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SEMA + CILO/FIR FDC0/125 (0%)17/124 (13.7%)101/124 (81.5%)
SEMA + PTM CILO/FIR1/124 (0.8%)13/122 (10.7%)97/122 (79.5%)
PTM SEMA + CILO/FIR FDC1/123 (0.8%)18/123 (14.6%)85/123 (69.1%)
PTM SEMA + PTM CILO/FIR0/85 (0%)11/84 (13.1%)60/84 (71.4%)
Most frequent serious events
Showing 10 of 63
Most frequent serious events
EventSEMA + CILO/FIR FDCSEMA + PTM CILO/FIRPTM SEMA + CILO/FIR FDCPTM SEMA + PTM CILO/FIR
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/1240/1223/1231/84
NephrolithiasisRenal and urinary disorders3/1240/1220/1231/84
Acute kidney injuryRenal and urinary disorders1/1242/1220/1231/84
Covid-19 pneumoniaInfections and infestations0/1240/1222/1230/84
AscitesGastrointestinal disorders0/1240/1220/1231/84
Prosthetic cardiac valve stenosisGeneral disorders0/1240/1220/1231/84
Diverticulitis intestinal perforatedInfections and infestations0/1240/1220/1231/84
SepsisInfections and infestations0/1240/1221/1231/84
Hip fractureInjury, poisoning and procedural complications0/1240/1220/1231/84
HyponatraemiaMetabolism and nutrition disorders0/1240/1220/1231/84
Most frequent other events
Showing 10 of 29
Most frequent other events
EventSEMA + CILO/FIR FDCSEMA + PTM CILO/FIRPTM SEMA + CILO/FIR FDCPTM SEMA + PTM CILO/FIR
NauseaGastrointestinal disorders59/12449/12229/12319/84
DiarrhoeaGastrointestinal disorders34/12425/12216/12315/84
ConstipationGastrointestinal disorders30/12426/12211/1237/84
VomitingGastrointestinal disorders27/12421/1227/1236/84
Covid-19Infections and infestations21/12415/12215/12314/84
Decreased appetiteMetabolism and nutrition disorders19/12420/1227/1235/84
FatigueGeneral disorders17/12417/1229/12311/84
Abdominal painGastrointestinal disorders11/12410/1226/12311/84
ArthralgiaMusculoskeletal and connective tissue disorders8/1246/12212/12311/84
HypoglycaemiaMetabolism and nutrition disorders14/1244/1223/1235/84

Baseline characteristics

The Safety Analysis Set included all participants who received at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)SEMA + CILO/FIR FDCSEMA + PTM CILO/FIRPTM SEMA + CILO/FIR FDCPTM SEMA + PTM CILO/FIRTotal
<=18 years00000
Between 18 and 65 years72736744256
>=65 years52495640197
Age, Continuous
Age, Continuous(years)SEMA + CILO/FIR FDCSEMA + PTM CILO/FIRPTM SEMA + CILO/FIR FDCPTM SEMA + PTM CILO/FIRTotal
Mean61 ± 10.461 ± 9.262 ± 9.563 ± 9.162 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)SEMA + CILO/FIR FDCSEMA + PTM CILO/FIRPTM SEMA + CILO/FIR FDCPTM SEMA + PTM CILO/FIRTotal
Female83857450292
Male41374934161
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SEMA + CILO/FIR FDCSEMA + PTM CILO/FIRPTM SEMA + CILO/FIR FDCPTM SEMA + PTM CILO/FIRTotal
Hispanic or Latino28233019100
Not Hispanic or Latino95999062346
Unknown or Not Reported10337
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SEMA + CILO/FIR FDCSEMA + PTM CILO/FIRPTM SEMA + CILO/FIR FDCPTM SEMA + PTM CILO/FIRTotal
American Indian or Alaska Native31127
Asian11915338
Native Hawaiian or Other Pacific Islander00000
Black or African American21159
White1001089866372
More than one race523414
Unknown or Not Reported315413
Region of Enrollment
Region of Enrollment(Participants)SEMA + CILO/FIR FDCSEMA + PTM CILO/FIRPTM SEMA + CILO/FIR FDCPTM SEMA + PTM CILO/FIRTotal
United States95998863345
Canada7712632
France5591029
Japan466117
Australia626216
Spain732214
08

Study locations

242 sites
  • University of Alabama at Birmingham Hospital
    Birmingham, Alabama 35233, United States
  • Digestive Health Specialists
    Dothan, Alabama 36305, United States
  • North Alabama Health Research, LLC
    Madison, Alabama 35758, United States
  • The Institution For Liver Health dba Arizona Liver Health
    Chandler, Arizona 85224, United States
  • Arizona Health Research
    Chandler, Arizona 85225, United States
  • The Institute for Liver Health DBA Arizona Liver Health
    Peoria, Arizona 85381, United States
  • Gastrointestinal Alliance - Sun City
    Sun City, Arizona 85351, United States
  • Adobe Clinical Research, LLC
    Tucson, Arizona 85712, United States
  • The Institution For Liver Health dba Arizona Liver Health
    Tucson, Arizona 85712, United States
  • Arkansas Diagnostic Center
    Little Rock, Arkansas 72204, United States
  • ARCare Center for Clinical Research
    Little Rock, Arkansas 72205, United States
  • Arkansas Gastroenterology
    North Little Rock, Arkansas 72117, United States
  • Southern California Research Center
    Coronado, California 92118, United States
  • University of California, San Francisco - Fresno
    Fresno, California 93701, United States
  • University of California, San Diego - Altman Clinical and Translational Research Institute
    La Jolla, California 92037, United States
  • Gastro Care Institute (Fibroscan)
    Lancaster, California 93534, United States
  • Digestive Health Research of Southern California
    Long Beach, California 90808, United States
  • Kaiser Permanente Los Angeles Medical Center
    Los Angeles, California 90027, United States
  • Keck Medical Center of USC Healthcare Consultation II
    Los Angeles, California 90033, United States
  • Biopharma Informatic, LLC
    Los Angeles, California 90035, United States
  • United Medical Doctors
    Murrieta, California 92563, United States
  • Knowledge Research Center
    Orange, California 92868, United States
  • Palmtree Clinical Research, Inc.
    Palm Springs, California 92262, United States
  • California Liver Research Institute
    Pasadena, California 91105, United States
  • Cadena Care Institute, LLC
    Poway, California 92064, United States
  • Stanford Medicine Outpatient Center
    Redwood City, California 94063, United States
  • Inland Empire Clinical Trials
    Rialto, California 92377, United States
  • University of California, Davis Medical Center
    Sacramento, California 95817, United States
  • Research and Education Inc.
    San Diego, California 92105, United States
  • TriWest Research Associates, LLC
    San Diego, California 92108, United States
  • Precision Research Institute
    San Diego, California 92114, United States
  • Medical Associates Research Group
    San Diego, California 92123, United States
  • Quest Clinical Research
    San Francisco, California 94115, United States
  • University of California, San Francisco - Liver Clinic
    San Francisco, California 94143, United States
  • San Jose Gastroenterology at One Health
    San Jose, California 95128, United States
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • South Denver Gastroenterology
    Englewood, Colorado 80113, United States
  • Yale Center for Clinical Investigation, Church Street Research Unit
    New Haven, Connecticut 06519, United States
  • Excel Medical Clinical Trials, LLC
    Boca Raton, Florida 33434, United States
  • Synergy Healthcare
    Bradenton, Florida 34208, United States
  • Southwest General Healthcare Center
    Fort Myers, Florida 33907, United States
  • University of Florida Hepatology Research at the Clinical and Translational Research Building
    Gainesville, Florida 32610, United States
  • Velocity Clinical Research, Hallandale Beach
    Hallandale, Florida 33009, United States
  • Indago Research and Health Center, Inc.
    Hialeah, Florida 33012, United States
  • Maya Research Center
    Hialeah, Florida 33016, United States
  • New Generation of Medical Research
    Hialeah, Florida 33016, United States
  • Evolution Clinical Research, INC
    Hialeah Gardens, Florida 33016, United States
  • Sunbright Health Medical Center
    Homestead, Florida 33032, United States
  • Nature Coast Clinical Research
    Inverness, Florida 34452, United States
  • UF Health Jacksonville-Gastroenterology Emerson
    Jacksonville, Florida 32224, United States
  • Encore Borland-Groover Clinical Research
    Jacksonville, Florida 32256, United States
  • Florida Research Institute
    Lakewood Rch, Florida 34211, United States
  • G+C Research Group
    Miami, Florida 33126, United States
  • Schiff Center for Liver Diseases/ University of Miami
    Miami, Florida 33136, United States
  • Advanced Pharma CR, LLC
    Miami, Florida 33147, United States
  • Century Research, LLC
    Miami, Florida 33173, United States
  • ProLive Medical Research, Corp
    Miami, Florida 33175, United States
  • International Medical Investigational Centers, Inc.
    Miami, Florida 33176, United States
  • Ocean Blue Medical Research Center, Inc
    Miami Springs, Florida 33166, United States
  • Gastroenterology Group of Naples
    Naples, Florida 34102, United States
  • Advanced Research Institute, Inc.
    New Port Richey, Florida 34653, United States
  • Ocala GI Research
    Ocala, Florida 34471, United States
  • Advanced Medical Research Center
    Port Orange, Florida 32127, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • Covenant Metabolic Specialists, LLC
    Sarasota, Florida 34240, United States
  • Charter Research
    Winter Park, Florida 32792, United States
  • Florida Medical Clinic, LLC
    Zephyrhills, Florida 33542, United States
  • Southeast Clinical Research LLC
    Dalton, Georgia 30720, United States
  • Gastrointestinal (GI) Specialists of Georgia
    Marietta, Georgia 30060, United States
  • Rush University Medical Group - Department of Hepatology
    Chicago, Illinois 60612, United States
  • Indiana University Health Enterprise Clinical Research Operations
    Indianapolis, Indiana 46202, United States
  • Gastroenterology Health Partners, PLLC
    New Albany, Indiana 47150, United States
  • Digestive Research Alliance of Michigan
    South Bend, Indiana 44635, United States
  • Iowa Digestive Disease Center, PC
    Clive, Iowa 50325, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Kansas Medical Clinic PA
    Topeka, Kansas 66606, United States
  • GI Alliance
    Baton Rouge, Louisiana 70809, United States
  • Combined Gastro Research, LLC
    Lafayette, Louisiana 70503, United States
  • Tandem Clinical Research GI, LLC
    Marrero, Louisiana 70072, United States
  • Delta Research Partners
    Monroe, Louisiana 71201, United States
  • Tulane University Health Sciences Center
    New Orleans, Louisiana 70112, United States
  • Oschner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • Louisiana Research Center, LLC
    Shreveport, Louisiana 71105, United States
  • Mercy Medical Center
    Baltimore, Maryland 21202, United States
  • Walter Reed National Military Medical Center
    Bethesda, Maryland 20889, United States
  • Woodholme Gastroenterology Associates
    Glen Burnie, Maryland 21061, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Greater Boston Gastroenterology
    Framingham, Massachusetts 01702, United States
  • Hawthorn Medical Associates
    South Dartmouth, Massachusetts 02747, United States
  • Michigan Medicine - University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Clinical Research Institute of Michigan, LLC
    Chesterfield, Michigan 48047, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinical Research Center
    Wyoming, Michigan 49519, United States
  • Huron Gastroenterology Associates
    Ypsilanti, Michigan 48197, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • GI Alliance
    Flowood, Mississippi 39232, United States
  • Southern Therapy and Advanced Research
    Jackson, Mississippi 39216, United States
  • Clinical Research Professionals
    Chesterfield, Missouri 63005, United States
  • GI Associates Research
    Columbia, Missouri 65201, United States

Showing the first 100 of 242 sites across 7 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Nov 2024, 39 months.

Results were first posted in Nov 2025, 1 year after primary completion.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 39 months is above that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2021
First posted
Jul 21, 2021
StartActual
Aug 9, 2021
Primary completionActual
Nov 12, 2024
CompletionActual
Dec 9, 2024
Results first posted
Nov 26, 2025
Last update
Nov 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04971785
Lead sponsor
Gilead Sciences
Collaborators
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jul 21, 2021
Start date
Aug 9, 2021
Primary completion
Nov 12, 2024
Completion
Dec 9, 2024
Results posted
Nov 26, 2025
Last update
Nov 26, 2025

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Semaglutide · Cilofexor · Firsocostat

Start the discussion